Sanofi, Cipla seal exclusive distribution partnership to expand reach of CNS portfolio in India

As part of this collaboration, Cipla will handle the distribution of Sanofi India's six CNS brands, including the industry-leading Frisium® brand of anti-epileptic drugs.

Sanofi India Limited, Sanofi Healthcare India Private Limited, and Cipla Limited announced an exclusive distribution and marketing partnership for the sale and promotion of Sanofi India's Central Nervous System (CNS) product line in India on March 26, according to an exchange filing.

As part of this collaboration, Cipla will handle the distribution of Sanofi India's six CNS brands, including the industry-leading Frisium® brand of anti-epileptic drugs.

According to the joint statement, Cipla will utilise its skills and solid India-wide network of distributors, institutions and market outreach programmes to expand access to these treatments for patients. Meanwhile, Sanofi India will continue to own, import, and manufacture its entire range of CNS products across plants in India and abroad.

Rodolfo Hrosz, Managing Director, Sanofi India Limited, said, "Sanofi India’s CNS products are leaders in their respective categories. These well-established brands already improve the lives of many patients across urban centres in the country. Cipla’s wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across India".

Achin Gupta, Chief Executive Officer – One India Business, Cipla Limited, stated, "Enhancing access to high-quality treatments is central to our purpose of ‘Caring for Life’. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central Nervous System is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients".